Today's Rundown Pfizer, Novartis sign on to accelerate gene therapies for rare diseases with US agencies Sanofi's €10B sales target for Dupixent? The 'megabrand' is more than halfway there, exec says Drug price reforms appear to be out of infrastructure bill FDA adds new restrictions, warning labels for breast implants following reports of cancer Alnylam founding CEO Maraganore steps down after pioneering RNA interference therapy Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset FDA outlines best practices for healthcare AI, alongside Canada, U.K. regulators Hinge Health bags $600M investment from Coatue, Tiger Global, boosting valuation to $6.2B Merck's big earnings in Q3 play second fiddle to enthusiasm for COVID pill's potential Telecom tycoon's phase 3 pancreatic cancer bet flames out, sending stock to the basement BCBSA, Nemours Children’s and Cityblock Health join cross-industry health equity pledge Science 37 partners with two CROs in Japan as part of decentralized trials push Featured Story | By Annalee Armstrong A cadre of big and small biotechs and pharmas plus nonprofit organizations have signed on to a new U.S. federal government initiative to go after gene therapies for rare diseases. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Shortly after Sanofi CEO Paul Hudson joined the company in 2019, he laid out an ambition to invest as much as necessary to turn the Regeneron-partnered antibody drug Dupixent into a megablockbuster. Two years later, Sanofi is well on its way. read more By Robert King Drug pricing provisions such as Medicare negotiation powers and Part D benefit redesign appear to be nixed from a massive infrastructure package which would also get rid of a controversial drug rebate rule. read more By Conor Hale The agency curbed the sale and distribution of both saline- and silicone gel-filled breast implants, including products from Allergan, Johnson & Johnson’s Mentor division, Sientra and Ideal Implant. read more By Angus Liu Alnylam’s founding CEO John Maraganore is leaving after a near 20-year run, handing the reins to Yvonne Greenstreet, currently the company’s president and chief operating officer. The longtime Alnylam chief seems to already have the next stop of his career planned out. read more By Ben Adams Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets as it dropped a biotech-partnered drug. read more By Conor Hale The 10 principles aim to underline what the agencies describe as “Good Machine Learning Practice” in the same vein as the industry quality standards centered around product manufacturing or clinical testing. read more By Heather Landi Fast-growing digital health company Hinge Health clinched $400 million in a financing round amid soaring demand for virtual physical therapy services. Hinge Health reports that its customer base has more than doubled year-over-year to over 575 enterprise customers as the company keeps pace with growing demand from millions of Americans seeking accessible care for back and joint pain. read more By Kevin Dunleavy On Thursday, when Merck reported third-quarter earnings that significantly exceeded expectations, the good news was almost an afterthought as the tantalizing future of COVID-19 oral treatment molnupiravir was the dominant topic of an investors call. read more By Nick Paul Taylor Rafael Pharmaceuticals' bet on the rock-hard pancreatic cancer indication has blown up in its face. The pivotal trial found devimistat had no effect on overall survival—and, as a kicker, another phase 3 in a blood cancer was stopped early for futility. read more By Anastassia Gliadkovskaya The Health Equity Pledge was developed over the past year by the Health Evolution Forum, a collective of payer, provider and life science leaders aiming to accelerate equity in healthcare and outcomes. read more By Kyle LaHucik Three weeks after going public, Science 37 is beefing up its presence in Asia via partnerships with two CROs in Japan. The collaborations with CMIC and 3H Medi Solution aim to expand access to virtual clinical trials in the region and elsewhere in Asia-Pacific. read more |
